Antisense modulation of human mdm2 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsLoren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia, Lex M. Cowsert
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
Claims20
An antisense compound 8 to 30 nucleobases in length targeted to nucleobases 1-308 of the 5′ untranslated region, 1776-1806 of the translation termination codon region or 1818-2370 of the 3′ untranslated region of a nucleic acid molecule encoding human mdm2, wherein said antisense compound modulates the expression of human mdm2.
An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 7, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 36, SEQ ID NO:
- 52, SEQ ID NO:
- 216, SEQ ID NO:
- 246, SEQ ID NO:
- 251, SEQ ID NO:
- 260, or SEQ ID NO:
- 264 which inhibits the expression of human mdm2.
An antisense compound up to 30 nucleobases in length targeted to a 5′ untranslated region of a nucleic acid molecule encoding a S-mdm2 transcript, wherein said antisense compound inhibits the expression of said S-mdm2 transcript and comprises at least an 8 nucleobase portion of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:7.
An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 15, SEQ ID NO:
- 56, SEQ ID NO:
- 57, SEQ ID NO:
- 120, SEQ ID NO:
- 126, SEQ ID NO:
- 160, SEQ ID NO:
- 177, SEQ ID NO:
- 180, or SEQ ID NO:
- 195.
An antisense compound consisting of SEQ ID NO:
- 60, 61, 69 or 70.
Dependencies are inferred from the claim text.